Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Policy + Initiatives

    Medical Countermeasures Surge Capacity Act of 2022 Introduced in Senate

    By Global Biodefense StaffFebruary 7, 2022
    Biodefense Funding and Legislation
    Share
    Facebook LinkedIn Reddit Email

    U.S. Senators Mitt Romney (R-UT) and Maggie Hassan (D-NH), members of the Health, Education, Labor, and Pensions (HELP) Committee, today introduced the Medical Countermeasures Surge Capacity Act of 2022, legislation to improve U.S. domestic manufacturing surge capacity and capabilities for biodefense and pandemic preparedness and response.

    Their legislation has been included in the recently released discussion draft of the HELP Committee’s bipartisan pandemic response bill, the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act).

    “We can’t be caught flatfooted when another public health emergency health like COVID-19 strikes,”said Senator Hassan.“We need to invest in American manufacturing and research so that we don’t have to rely on a country like China during a crisis. New England is home to some of the best medical research companies in the world – this bipartisan bill would make critical investments now and better ensure that we are prepared for the threats of tomorrow.”

    However, BARDA’S ability to support manufacturing capacity for medical countermeasures has only been used for pandemic influenza, and further restricted in the type of operationally ready facilities the agency can support. These limitations hamper our nation’s ability to support, maintain, and improve domestic manufacturing surge capacity for any qualified medical countermeasure.

    The Medical Countermeasures Surge Capacity Act of 2022 expands BARDA’s authority to ensure a warm base for any qualified medical countermeasure, pandemic, or epidemic product. With this expanded authority, BARDA can support the entire lifecycle of a countermeasure—from initial research and development to surge manufacturing capacity and capabilities in an emergency.

    Additionally, the Medical Countermeasures Surge Capacity Act of 2022 builds in important coordination with the Food and Drug Administration (FDA) to ensure manufacturing facilities maintain good manufacturing practices and are in compliance with FDA inspections.

    ASPR BARDA Editor Pick HHS Legislative
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleIn Pictures: Veterinary Civic Action Program in Niger
    Next Article USAMRIID Study Reveals Ebola Virus Can Hide in Brain

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.